Desmoplastic melanoma with sarcomatoid dedifferentiation

American Journal of Surgical Pathology

Volumn 38, Issue 6, 2014, Pages 864-870

  Kiuru, Maija ^a   Mcdermott, Gregory ^a   Berger, Michael ^a   Halpern, Allan C ^a   Busam, Klaus J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biphenotypic tumor; Desmoplastic melanoma; Next generation sequencing; Sarcoma

Indexed keywords

TUMOR MARKER;

AGED; ARTICLE; BIOPSY; CASE REPORT; CELL DEDIFFERENTIATION; CHEMISTRY; GENETICS; HEAD AND NECK TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIXED TUMOR; PATHOLOGY; PHENOTYPE; SARCOMA; SCALP; SKIN TUMOR;

AGED; BIOPSY; CELL DEDIFFERENTIATION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NEOPLASMS, COMPLEX AND MIXED; PHENOTYPE; SARCOMA; SCALP; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900840963     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000201     Document Type: Article

References (33)

1. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer. 1971;28:914-936
2. Chen LL, Jaimes N, Barker CA, et al. Desmoplastic melanoma: A review. J Am Acad Dermatol. 2013;68:825-833
3. Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: A systematic review. Br J Dermatol. 2005;152:673-678
4. Busam KJ. Desmoplastic melanoma. Clin Lab Med. 2011;31: 321-330
5. Palla B, Su A, Binder S, et al. SOX10 expression Distinguishes desmoplastic melanoma from its histologic mimics. Am J Dermatopathol. 2013;35:576-581
6. Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol. 2008;35: 1014-1019
7. Ramos-Herberth FI, Karamchandani J, Kim J, et al. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 2010;37:944-952
8. Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: Reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol. 2004;28:1518-1525
9. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: A pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol. 2005;12:207-213
10. George E, McClain SE, Slingluff CL, et al. Subclassification of desmoplastic melanoma: Pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol. 2009;36:425-432
11. Miller DD, Emley A, Yang S, et al. Mixed versus pure variants of desmoplastic melanoma: A genetic and immunohistochemical appraisal. Mod Pathol. 2012;25:505-515
12. Mohamed A, Gonzalez RS, Lawson D, et al. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol. 2013;21:506-510
13. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754-1760
14. DePristo MA, Banks E, Poplin R, et al A framework for variation Discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491-498
15. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213-219
16. Kacerovska D, Michal M, Kutzner H, et al. Metastatic desmoplastic malignant melanoma associated with low-grade myofibroblastic sarcoma. Am J Dermatopathol. 2009;31:490-494
17. De Mattos-Arruda L, Bidard FC, Won HH, et al. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. Mol Oncol. 2014;8:150-158
18. Tothill RW, Li J, Mileshkin L, et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013. DOI: 10.1002/path.4251. [Epub ahead of print].
19. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221
20. Kiuru M, McDermott G, Coit D, et al. Basal cell carcinosarcoma with PTCH1 mutations in both epithelial and sarcomatoid primary tumor components and in the sarcomatoid metastasis. Am J Surg Pathol. 2013;38:138-142
21. Arsenovic N, Sen S, Naik V, et al. Trichilemmal cyst with carcinoma in situ within an atypical fibroxanthoma. Am J Dermatopathol. 2009;31:587-590
22. Hyatt AM, Mutasim DF, Spicknall KE. Collision of atypical fibroxanthoma and acantholytic squamous cell carcinoma in situ. Am J Dermatopathol. 2012;34:563-564
23. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954
24. Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in Desmoplastic melanomas. Cancer. 2005;103: 788-792
25. Reifenberger J, Knobbe CB, Sterzinger AA, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer. 2004;109:377-384
26. Kunz M, Dannemann M, Kelso J. High-Throughput sequencing of the melanoma genome. Exp Dermatol. 2013;22:10-17
27. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000;157:967-972
28. Bender RP, McGinniss MJ, Esmay P, et al. Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in Deep penetrating nevi. Mod Pathol. 2013;26:1320-1328
29. Gutzmer R, Herbst RA, Mommert S, et al. Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in Desmoplastic neurotropic melanoma. Hum Genet. 2000;107:357-361
30. Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol. 2005;12:92-102
31. Gerami P, Jewell SS, Pouryazdanparast P, et al. Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn. 2011;13:352-358
32. Bastian BC, Wesselmann U, Pinkel D, et al. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol. 1999;113:1065-1069
33. Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014. [Epub ahead of print].